Unknown

Dataset Information

0

Integrin ?4?7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques.


ABSTRACT: Infusion of a simianized anti-?4?7 mAb (Rh-?4?7) just before and following SIV infection protected rhesus macaques from developing AIDS and partially from vaginal SIV acquisition. Recently, short-term treatment with Rh-?4?7 in combination with cART was found to lead to prolonged viral suppression after withdrawal of all therapeutic interventions. The humanized form of Rh-?4?7, vedolizumab, is a highly effective treatment for inflammatory bowel disease. To clarify the mechanism of action of Rh-?4?7, naive macaques were infused with Rh-?4?7 and sampled in blood and tissues before and after treatment to monitor several immune cell subsets. In blood, Rh-?4?7 increased the CD4+ and CD8+ T cell counts, but not B cell counts, and preferentially increased CCR6+ subsets while decreasing CD103+ and CD69+ lymphocytes. In mucosal tissues, surprisingly, Rh-?4?7 did not impact integrin ?4+ cells, but decreased the frequencies of CCR6+ and CD69+ CD4+ T cells and, in the gut, Rh-?4?7 transiently decreased the frequency of memory and IgA+ B cells. In summary, even in the absence of inflammation, Rh-?4?7 impacted selected immune cell subsets in different tissues. These data provide new insights into the mechanisms by which Rh-?4?7 may mediate its effect in SIV-infected macaques with implications for understanding the effect of treatment with vedolizumab in patients with inflammatory bowel disease.

SUBMITTER: Calenda G 

PROVIDER: S-EPMC5760460 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrin α<sub>4</sub>β<sub>7</sub> Blockade Preferentially Impacts CCR6<sup>+</sup> Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques.

Calenda Giulia G   Keawvichit Rassamon R   Arrode-Brusés Géraldine G   Pattanapanyasat Kovit K   Frank Ines I   Byrareddy Siddappa N SN   Arthos James J   Cicala Claudia C   Grasperge Brooke B   Blanchard James L JL   Gettie Agegnehu A   Reimann Keith A KA   Ansari Aftab A AA   Martinelli Elena E  

Journal of immunology (Baltimore, Md. : 1950) 20171201 2


Infusion of a simianized anti-α<sub>4</sub>β<sub>7</sub> mAb (Rh-α<sub>4</sub>β<sub>7</sub>) just before and following SIV infection protected rhesus macaques from developing AIDS and partially from vaginal SIV acquisition. Recently, short-term treatment with Rh-α<sub>4</sub>β<sub>7</sub> in combination with cART was found to lead to prolonged viral suppression after withdrawal of all therapeutic interventions. The humanized form of Rh-α<sub>4</sub>β<sub>7</sub>, vedolizumab, is a highly effecti  ...[more]

Similar Datasets

| S-EPMC7839271 | biostudies-literature
| S-EPMC4226795 | biostudies-literature
| S-EPMC5539107 | biostudies-literature
| S-EPMC5899190 | biostudies-literature
| S-EPMC8300572 | biostudies-literature
| S-EPMC8184841 | biostudies-literature
2018-02-19 | GSE110617 | GEO
| S-EPMC5546709 | biostudies-literature
| S-EPMC8262352 | biostudies-literature
| S-EPMC7249223 | biostudies-literature